

IANPHI-Europe lessons learned from European NPHI responses to COVID-19

Working Agenda

Date & Time: 5 November 15:00 – 17:00 CET.

Zoom connection details: If you have not already done so, you can register for the meeting here: [redacted] (10)(2g) Please connect to the webinar using a computer rather than a mobile phone. Please contact the Secretariat if you have any issues.

Discussion format: The discussion will be organised around a series of guiding questions including brief (3 minute) presentations from IANPHI members. After a group of presentations, open Q&A will follow. Though not necessary, speakers are welcome to prepare a couple of PowerPoint slides for their presentations if they wish so. A final section will allow for participants to discuss openly around responses to COVID-19.

Logistics and follow up: Please note that the meeting will not be recorded, although a written summary will be prepared by the IANPHI Secretariat without verbatim comments attributed to individuals. This summary will support the organisation by a working group of the COVID-19 discussion during the IANPHI Annual Meeting. When taking the floor to speak, please state your name and institute.

Proposed Working Agenda

<u>Section</u>	<u>Presenters & Description</u>	<u>Timing</u>
1. Introduction to the meeting and framing of the discussion	[redacted] 5.1.2e [redacted] 5.1.2e	15:00 – 15:05
2. The role of NPHIs as governments’ trusted scientific advisor	<i>This section will explore the relationships between the NPHI and primarily government structures (Ministries of Health, etc.) and also other significant relationships with agencies and the media. The main objectives will be to discuss levels of trust, communication channels and clear distinctions of roles and responsibilities.</i>	15:05 – 16:00
2.1. What role did the institute play in providing strategic and operational planning advice to national government and local and regional organisations?	<i>Italy ISS</i> [redacted] 5.1.2e [redacted] <i>Estonian National Institute for Health Development</i> [redacted] 5.1.2e [redacted] 5.1.2e	

<p>2.2. To what extent was the institute asked to operate outside of its mandate and why?</p>	<p><u>Public Health Wales</u> 5.1.2e</p>	
<p>2.3. Was the institute considered a trusted advisor by the authorities? What were the main difficulties encountered by the institute to maintain a high level of trust? Was there any breach in that trust and why? What actions were undertaken to solve this? What could have been improved?</p>	<p><u>Israel CDC</u> 5.1.2e</p>	
<p>2.4. What impact has the media had on the institute's response to COVID-19? How has the institute dealt with any negative media reactions?</p>	<p><i>Discussion introduced by</i> 5.1.2e</p>	
<p>2.5. What dimensions in international coordination went well, and what could be improved for the benefit of the NPHIs? And who is responsible for such improvements, if not the NPHIs themselves? How should collaboration on COVID-19 be organised within IANPHI in the months to come?</p>	<p><i>Discussion introduced by</i> 5.1.2e</p>	
<p><i>Open discussion around grouped questions and presentations</i></p>		
<p>3. The capacities a NPHI must mobilize to respond to this pandemic</p>	<p><i>This section will explore what capacities (resources and expertise) NPHIs have needed to and will need to mobilise to respond to challenges. The main objective will be to discuss what organisational changes took place / need to take place and how these changes were made.</i></p>	<p>16:00 – 16:35</p>
<p>3.1. How has the institute managed to scale up resources to deal with COVID-19 (internal reorganization, cancellation of other activities, extra staff, external support, information systems?)</p>	<p><u>Santé publique France</u> (5.1.2a 5.1.2e</p>	
<p>3.2. Was scaling-up of testing for SARS-CoV-2 effective? What were the challenges and good practices that emerged through scaling-up?</p>	<p><u>RKI</u> 5.1.2e</p>	

3.3. Has the institute communicated guidance directly to the general public? If so, what was the process for messages to be developed, approved and disseminated?	<u>BZgA</u> 5.1.2e	
<i>Open discussion around grouped questions and presentations</i>		
4. Open discussion	Any other COVID-19 areas of discussion, moderated by 5.1.2e. <i>Please refer to the list of areas identified for the IANPHI lessons learned initiative. Examples may include; evaluating the impacts of containment measures, vaccination strategies and reinforcing international collaboration through IANPHI</i>	16:35 – 16:55
5. Conclusions	Concluding remarks by 5.1.2e	16:55- 17:00